Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 18/20 | 0.58 |
| ▸ | FGFR2 | P21802 | 12/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.51 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.51 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30045172 | 1.00 | FGFR4 (0.58) | FGFR4FGFR2FGFR1CYP2C9CYP2C8 | |
| SCHEMBL30045354 | 0.95 | FGFR4 (0.59) | FGFR4FGFR2FGFR1CYP2C9CYP2C8 | |
| SCHEMBL21240459 | 0.95 | FGFR4 (0.59) | FGFR4FGFR2FGFR1CYP2C9CYP2C8 | |
| SCHEMBL21240616 | 0.95 | FGFR4 (0.58) | FGFR4FGFR2FGFR1CYP2C9CYP2C8 | |
| SCHEMBL29577596 | 0.95 | FGFR4 (0.58) | FGFR4FGFR2FGFR1CYP2C9CYP2C8 | |
| SCHEMBL21240368 | 0.92 | FGFR4 (0.58) | FGFR4FGFR2FGFR1CYP2C9CYP2C8 | |
| SCHEMBL30045728 | 0.92 | FGFR4 (0.58) | FGFR4FGFR2FGFR1CYP2C9CYP2C8 | |
| SCHEMBL21320826 | 0.92 | FGFR4 (0.58) | FGFR4FGFR2FGFR1CYP2C9CYP2C8 | |
| SCHEMBL21240525 | 0.91 | FGFR2 (0.60) | FGFR4FGFR2FGFR1 | |
| SCHEMBL30046262 | 0.91 | FGFR2 (0.60) | FGFR4FGFR2FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11555036-B2 | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-01-17 | — | — | US | disclosed |
| US-10968220-B2 | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-04-06 | — | — | US | disclosed |
| US-10968220-B2 | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-04-06 | — | — | US | disclosed |
| US-20190270742-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2019-09-05 | — | — | US | disclosed |
| US-20190270742-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2019-09-05 | — | — | US | disclosed |
| EP-3524603-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2019-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270742-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | FGFR4, FGFR2, FGFR1 | FGFR4 1/4885FGFR2 2/4885FGFR1 3/4885 |
| US-11555036-B2 | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof | FGFR4, FGFR2, FGFR1 | FGFR4 1/4885FGFR2 2/4885FGFR1 3/4885 |
| US-10968220-B2 | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof | FGFR4, FGFR2, FGFR1 | FGFR4 1/4885FGFR2 2/4885FGFR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.